Basic Information
| LncRNA/CircRNA Name | MFI2-AS1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qRT-PCR, RIP, Western blot |
| Sample | HCC tissues,cell lines |
| Expression Pattern | up-regulated |
| Function Description | MFI2-AS1 crucially acted in HCC progression via functioning as miR-134 sponge to upregulating FOXM1 expression, and was conducive to the promotion of better understanding the direct diagnostics and iatreusiology of lncRNA in HCC. |
| Pubmed ID | 32106369 |
| Year | 2020 |
| Title | LncRNA MFI2-AS1 promotes HCC progression and metastasis by acting as a competing endogenous RNA of miR-134 to upregulate FOXM1 expression |
External Links
| Links for MFI2-AS1 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |